What we found on the web about Argatroban
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. [1] In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or ...
Current members of this class include argatroban, lepirudin, bivalirudin, and dabigatran. An oral direct thrombin inhibitor, ximelagatran (Exanta) was denied approval by the Food ...
The drug is not sold by any other names and no generic form is available. The molecule's systematic chemical name is 1-[5-][(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro ...
ARGATROBAN Suggested Guidelines for Use University of Washington Medical Center Dept of Pharmacy *****FOR PHYSICIAN USE ONLY***** This is not intended as a nurse-managed protocol ...
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia B. E. Lewis, MD; D. E. Wallis, MD; S. D. Berkowitz, MD; W. H. Matthai, MD; J. Fareed, PhD; J ...
argatroban /ar·gat·ro·ban/ (ahr-gat´ro-ban″) an anticoagulant used in the prophylaxis and treatment of heparin-induced thrombocytopenia. argatroban
Consumer information about the medication ARGATROBAN - INJECTABLE , includes side effects, drug interactions, recommended dosages, and storage information. Read more about the ...
Argatroban Chemical formula: Drug Forms: Argatroban Solution for injection (below) Argatroban injection Español: Argatroban, Solución para inyección
Version: 2.5: Creation Date: 2005-06-13 13:24:05: Update Date: 2009-06-23 18:07:23: Primary Accession Number: DB00278: Secondary Accession Number: APRD00105; Name
This is a website for Argatroban ... The video is a representation of how heparin-induced thrombocytopenia is thought to occur and how the direct thrombin inhibitor argatroban ...
Here is what users have to say about Argatroban

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!